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ABSTRACT
Introduction Reaching high coverage of HIV testing 
remains essential for HIV diagnosis, treatment and 
prevention. We evaluated the effectiveness and safety of 
door- to- door distribution of HIV self- testing (HIVST) kits in 
rural Malawi.
Methods This cluster randomised trial, conducted 
between September 2016 and January 2018, used 
restricted 1:1 randomisation to allocate 22 health facilities 
and their defined areas to door- to- door HIVST alongside 
the standard of care (SOC) or the SOC alone. The study 
population included residents (≥16 years). HIVST kits were 
provided door- to- door by community- based distribution 
agents (CBDAs) for at least 12 months. The primary 
outcome was recent HIV testing (in the last 12 months) 
measured through an endline survey. Secondary outcomes 
were lifetime HIV testing and cumulative 16- month 
antiretroviral therapy (ART) initiations, which were captured 
at health facilities. Social harms were reported through 
community reporting systems. Analysis compared cluster- 
level outcomes by arm.
Results Overall, 203 CBDAs distributed 273 729 HIVST 
kits. The endline survey included 2582 participants in 11 
HIVST clusters and 2908 participants in 11 SOC clusters. 
Recent testing was higher in the HIVST arm (68.5%, 
1768/2582) than the SOC arm (48.9%, 1422/2908), with 
adjusted risk difference (RD) of 16.1% (95% CI 6.5% to 
25.7%). Lifetime testing was also higher in the HIVST arm 
(86.9%, 2243/2582) compared with the SOC arm (78.5%, 
2283/2908; adjusted RD 6.3%, 95% CI 2.3% to 10.3%). 
Differences were most pronounced for adolescents aged 
16–19 years (adjusted RD 18.6%, 95% CI 7.3% to 29.9%) 
and men (adjusted RD 10.2%, 95% CI 3.1% to 17.2%). 
Cumulative incidence of ART initiation was 1187.2 and 
909.0 per 100 000 population in the HIVST and SOC arms, 
respectively (adjusted RD 309.1, 95% CI −95.5 to 713.7). 
Self- reported HIVST use was 42.5% (1097/2582), with 
minimal social harms reported.
Conclusion Door- to- door HIVST increased recent and 
lifetime testing at population level and showed high safety, 
underscoring potential for HIVST to contribute to HIV 
elimination goals in priority settings.
Trial registration number NCT02718274.
INTRODUCTION
In 2016, an estimated 19.4 million people 
were living with HIV in southern and eastern 
Africa.1 Despite expansion of HIV testing 
and treatment programmes, one- quarter of 
people living with HIV remained unaware 
of their HIV status. HIV testing gaps were 
highest in adolescents and men, including 
in Malawi.1 In 2015–2016, the proportion 
of undiagnosed HIV was 46% among HIV- 
positive adolescents and young adults aged 
15–24 years, the highest across age groups.2 
Of men with HIV, 28% were unaware of their 
status compared with 20% of women with 
Key questions
What is already known?
 ► HIV self- testing (HIVST) can further extend cover-
age of HIV testing among underserved population 
subgroups.
 ► Limited data were previously available on the effec-
tiveness and safety of HIVST from rural, underserved 
populations in high HIV prevalence settings.
What are the new findings?
 ► Door- to- door distribution of HIVST kits by 
community- based distribution agents increased 
recent HIV testing and lifetime HIV testing, with dif-
ferences most pronounced among adolescents aged 
16–19 years and men.
 ► Cumulative incidence of antiretroviral therapy ini-
tiations was not shown to increase for the overall 
16- month intervention period.
 ► Self- reported HIVST use was 42.5%, with minimal 
social harms reported.
What do the new findings imply?
 ► Door- to- door HIVST demonstrates significant poten-
tial to contribute to HIV elimination goals in priority 
settings.
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HIV.2 Reaching high coverage of HIV testing remains 
essential for HIV diagnosis, treatment and prevention,3 
but access of facility- based HIV services can be limited by 
social, economic and health system barriers.4–6
Community- based HIV testing strategies can iden-
tify HIV- positive persons at earlier stages of infection 
and improve antiretroviral therapy (ART) initiation 
and retention when provided with universal treatment 
services.7 8 Provision of HIV self- testing (HIVST) 
through community- based approaches can further 
extend coverage of HIV testing among underserved 
population subgroups.9 In Malawi, urban community- 
based distribution of HIVST kits achieved high uptake, 
with offer of home- based HIV care further increasing 
demand for ART.10 11 Introducing HIVST with door- to- 
door HIV testing services (HTS) by community health 
workers increased knowledge of HIV status among urban 
Zambians.12 Community- based HIVST is therefore a 
promising approach for providing HIV testing, though 
lower literacy and healthcare access among rural popula-
tions could influence uptake of self- care technologies.13 
Limited data were previously available on the effective-
ness and safety of HIVST from rural, underserved popu-
lations in high HIV prevalence settings.
In this study, we used a cluster randomised trial to eval-
uate the effectiveness and safety of door- to- door distribu-
tion of HIVST kits in rural Malawi. Specifically, we aimed 
to assess whether distribution of HIVST kits through 
community- based distribution agents (CBDAs) increased 
the proportion of the population who tested for HIV 
and were initiated on ART at cluster level. Our study is 
part of a multicountry evaluation of community- based 
distribution of HIVST kits under the Unitaid/Popula-
tion Services International (PSI) HIV Self- Testing Africa 
(STAR) Initiative.
METHODS
Design, setting and participants
We conducted a parallel cluster randomised trial of 
door- to- door distribution of HIVST kits.14 The study 
was based in 22 government primary health centres 
and their defined areas in four high HIV prevalence 
districts (Blantyre, Machinga, Mwanza, Neno). A cluster 
randomised design was adopted since the intervention 
was implemented at the health facility level. The study 
team enrolled health facilities providing HIV testing and 
ART services to rural communities in their catchment 
areas, with verbal consent obtained from facility repre-
sentatives. Boundaries were drawn for: (1) the facility 
catchment area, and (2) the evaluation area within the 
facility catchment area. The intervention was delivered 
throughout the facility catchment area, while primary 
and secondary outcomes were measured among resi-
dents from the evaluation area. Specifically, the study 
population included residents aged 16 years and older 
from the evaluation area.
Randomisation
The 22 health facilities were randomised 1:1 to the HIVST 
intervention alongside the standard of care (SOC) or the 
SOC alone, which primarily consisted of facility- based 
HTS (figure 1). A computer- generated random sample 
was drawn by MN from 150 855 unique combinations of 
allocating health facilities to one of the two study arms, 
restricted by district, catchment population size, number 
of HTS clients and the proportion of clients testing HIV 
positive.15 The final allocation was assigned at a public 
ceremony on 21 March 2016. Numbered balls were 
selected by community and government representatives 
from an opaque bag that corresponded to a unique alloca-
tion. Blinding of the implementation team and residents 
was not feasible due to the nature of the intervention, but 
masking was maintained where possible, including data 
collection, management and analysis without reference 
to the study arms.
A planned second randomisation of home- based HIV 
care in the HIVST arm was not implemented due to 
delays in initiating the intervention, leaving an insuffi-
cient interval for assessment.14
Procedures
The HIVST intervention was delivered for at least 12 
months within the evaluation area of eligible health facili-
ties before expanding to the rest of the facility catchment 
area. HIVST kits were distributed by existing CBDAs, who 
provided reproductive health products prior to HIVST 
distribution, and newly recruited CBDAs selected in 
consultation with village heads.
PSI Malawi conducted 1- week trainings based on an 
HIVST training curriculum developed in collaboration 
with the Ministry of Health. The training included basic 
information on HIV diagnosis and treatment; promoting 
SOC arm
HIVST arm
Figure 1 Map of trial clusters in Malawi. Map of Blantyre, 
Machinga, Mwanza and Neno district with government health 
facilities and their defined clusters. Malawi National Spatial 
Data Centre, http://www.masdap.mw/. HIVST, HIV self- 
testing; SOC, standard of care.
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HIVST using social marketing; using kits and interpreting 
results; providing pretest and post- test information and 
support, including referral for confirmatory HIV testing 
and ART following a positive self- test; anticipating and 
managing social harms; storing kits; and collecting data. 
National HIV testing and counselling practices and prin-
ciples on voluntariness, consent and protection of client 
privacy and confidentiality were also covered in the 
training.
CBDAs then provided the OraQuick HIV Self- Test 
(OraSure Technologies, Thailand), along with locally 
adapted instructions for use,16 an opaque envelope for 
disposal and a self- referral card to facilitate linkage to 
routine HIV services at health facilities. In their respec-
tive areas, CBDAs distributed HIVST kits door- to- door 
or on request to residents aged 16 years and older, with 
their sociodemographic characteristics recorded in regis-
ters. Residents could self- test with CBDAs or in private. If 
residents elected to self- test privately, CBDAs followed up 
within 7 days of distribution to provide optional post- test 
support. Disclosure was not required, and HIVST results 
were not recorded in registers. Residents were also asked 
to place their used kits in envelopes to be returned to 
CBDAs or deposited in locked boxes located centrally in 
each village. PSI provided monthly supervision to verify 
data in CBDA registers, collect used kits and restock 
supplies. CBDAs were remunerated for each kit distrib-
uted (MWK100/US$0.15) and each kit distributed with 
linkage to HIV care (MWK150/USD$0.23).
The SOC in both arms included HIV testing and ART 
services under the Ministry of Health, offered primarily 
at health facilities. Standard HIV testing used blood- 
based rapid diagnostic testing algorithms, with ART initi-
ated immediately following a confirmed HIV diagnosis.
Outcomes and measurement
The primary outcome compared between arms the 
proportion of individuals aged 16 years and older who 
self- reported recent testing for HIV (in the last 12 
months), measured at cluster level using an endline 
survey. Secondary outcomes compared (1) self- reported 
lifetime HIV testing, and (2) cumulative 16- month inci-
dence of ART initiations per 100 000 population, which 
was ascertained using ART clinic records during the 
intervention period.
HIV testing outcomes were measured through a cross- 
sectional survey administered at the end of the interven-
tion period. In each evaluation area, two villages with a 
minimum of 250 residents aged 16 years and older were 
randomly selected, with one village surveyed at endline 
and one village surveyed at baseline. The baseline survey 
was conducted prior to the intervention to adjust for 
imbalance between arms in the primary outcome.
Households in the evaluation villages were enumerated 
and randomly selected to provide a sample of at least 250 
participants per village. All individuals aged 16 years and 
older in selected households were eligible for the survey, 
with multiple visits for interviews attempted to maximise 
the response rate. Informed verbal consent or assent was 
obtained. Participants were then interviewed on house-
hold and sociodemographic characteristics and prior use 
of HIV testing, treatment and prevention services.
ART initiation data were extracted from registers at 
each of the health facilities for the 16- month interven-
tion period and the 12- month period preceding the 
intervention. Eligibility criteria included ART patients 
aged 16 years and older from the evaluation area. Popu-
lation estimates for the evaluation area, which were used 
as the denominator for the ART outcome, were obtained 
from facility and village registers.
The proportion of lifetime HIVST use and the 
number of HIVST kits distributed were evaluated using 
the endline survey and CBDA registers. Adverse events 
related to HIVST were also measured using the endline 
survey in addition to a community reporting system 
established in evaluation villages to identify and manage 
potential adverse events.17 Community stakeholders, 
including village heads, community health workers, reli-
gious leaders and police officers, documented, investi-
gated and managed social harms related to HIV testing 
and self- testing. Adverse events were reported to the study 
team and assessed, categorised by severity and followed 
up as appropriate.17
Sample size
With 11 clusters per arm and 250 participants per cluster, 
we had at least 80% power at a 5% significance level to 
detect a 30% relative increase in the primary outcome of 
recent HIV testing in the HIVST arm, assuming 25%–40% 
coverage in the SOC arm.18 The study was also powered 
to identify a 45% relative increase in lifetime HIV testing 
in the HIVST arm, assuming 42%–60% coverage in the 
SOC arm. The sample size was calculated using a coeffi-
cient of variation (k) in clusters of 0.25.15
Statistical analysis
We conducted an intention- to- treat analysis based on 
cluster assignment to study arms and used methods appro-
priate for cluster randomised trials.15 The risk difference 
(RD) and risk ratio were calculated respectively from 
cluster- level risks and log risks, which were compared by 
arm using a t- test. For HIV testing outcomes, we adjusted 
for imbalances in individual- level covariates based on a 
two- stage approach.15 The first stage used logistic regres-
sion with individual- level covariates to obtain predicted 
values, which were summed at the cluster level and 
applied to calculate the difference and ratio of observed 
and predicted values. The second stage used linear 
regression of covariate- adjusted residuals obtained from 
the first stage and included the study arm. To adjust for 
imbalance in the primary outcome prior to the interven-
tion, the cluster- level baseline covariate of recent HIV 
testing was also included in the regression model. The 
ART initiation outcome adjusted for ART uptake in the 
12- month preintervention period.
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For recent HIV testing, a priori subgroup analyses were 
specified by sex, age group (16–19 years, 20 years and 
older) and socioeconomic status (lowest, middle, highest 
strata). Post hoc analysis used alternative categories of 
age group (16–19 years, 20–39 years, 40 years and older). 
Further, subgroup analyses were conducted for lifetime 
HIV testing by sex, age group and socioeconomic status, 
and for ART initiations by intervention period (0–5, 6–11, 
12–16 months). Statistical analysis used Stata V.14.0.
RESULTS
Implementation of the intervention was staggered, 
starting from September to December 2016, and contin-
uing until January 2018. Overall, 203 CBDAs (cluster 
mean 18.5) distributed 273 729 HIVST kits (cluster mean 
24 884.45) throughout the catchment area of health 
facilities, including evaluation and non- evaluation areas 
(online supplemental table 1). The volume of kits distrib-
uted was similar by sex, with 50.2% (n=137 433) of kits 
delivered to men.
The population in the evaluation area included 44 
390 residents in 11 clusters in the HIVST arm and 51 
488 residents in 11 clusters in the SOC arm. Partici-
pants were recruited for the endline survey between 
October 2017 and January 2018. The trial flow diagram is 
reported in figure 2. The endline survey included 77.0% 
(2582/3355) of enumerated residents in the HIVST arm 
and 78.6% (2908/3699) of enumerated residents in the 
SOC arm, with few eligible residents refusing to partici-
pate (10/7054).
Population characteristics for the endline survey are 
summarised in table 1. The proportion of men was 42.6% 
(2339/5490) and the median age was 31 years old. The 
majority of participants did not have beyond primary- 
level education (84.9%, 4661/5490). Most characteristics 
were well balanced by arm. Differences were observed for 
marital status, with 69.5% (1795/2582) married in the 
HIVST arm and 63.2% (1838/2908) married in the SOC 
arm.
The baseline survey was administered between May and 
August 2016. Of listed individuals, 78.5% (2809/3577) 
and 74.7% (2664/3567) were surveyed in the HIVST and 
SOC arms, respectively (online supplemental tables 2 and 
3). Baseline coverage of HIV testing in the last 12 months 
was higher in the HIVST arm (56.0%, 1574/2809) than 
the SOC arm (48.4%, 1289/2664; table 1). We therefore 
adjusted for baseline differences in analysis of primary 
and secondary outcomes. Self- reported lifetime use of 
HIVST at baseline was limited (7/5473).
Primary outcome
At endline, recent HIV testing (in the last 12 months) was 
higher in the HIVST arm (68.5%, 1768/2582) compared 
with the SOC arm (48.9%, 1422/2908), with adjusted RD 
of 16.1% (95% CI 6.5% to 25.7%; table 2; online supple-
mental figure 1). In subgroup analysis, the intervention 
had a more pronounced effect among adolescents aged 
16–19 years (adjusted RD 26.1%, 95% CI 12.9% to 39.2%) 
than adults aged 20 years and older (adjusted RD 14.7%, 
95% CI 4.8% to 24.6%), though data were consistent with 
no interaction effect (p value for interaction=0.18). Post 
Figure 2 Trial flow diagram. Flow diagram of the cluster randomised trial. HIVST, HIV self- testing.
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hoc analysis found similar differences among adults aged 
20–39 years and adults 40 years and older (online supple-
mental table 4). While the difference in the proportion 
of recent testing was also higher for men (adjusted RD 
20.6%, 95% CI 7.1% to 34.0%) compared with women 
(adjusted RD 12.8%, 95% CI 4.0% to 21.6%), there 
was weak evidence for interaction (p=0.07). In terms of 
socioeconomic status, the effect of the intervention was 
greater among participants in the highest strata (adjusted 
RD 20.2%, 95% CI 8.3% to 32.1%) than the lowest strata 
(adjusted RD 13.0%, 95% CI 1.1% to 24.8%). However, 
there was no evidence for interaction (highest vs lowest 
strata: p value for interaction=0.18).
Secondary outcomes
Lifetime HIV testing was higher in the HIVST arm (86.9%, 
2243/2582) than the SOC arm (78.5%, 2283/2908; 
adjusted RD 6.3%, 95% CI 2.3% to 10.3%; table 2; online 
supplemental figure 1). In exploratory analysis, the effect 
of the intervention was larger for adolescents aged 16–19 
years (adjusted RD 18.6%, 95% CI 7.3% to 29.9%) than 
adults aged 20 years and older (adjusted RD 4.4%, 95% 
CI 0.5% to 8.2%; p value for interaction=0.02), and for 
men (adjusted RD 10.2%, 95% CI 3.1% to 17.2%) than 
women (adjusted RD 3.4%, 95% CI −0.9% to 7.7%; p 
value for interaction=0.07; online supplemental table 4). 
The intervention effect on lifetime testing was similar in 
the lowest and highest socioeconomic strata and close to 
zero for the middle strata.
Cumulative incidence of ART initiation captured at 
health facilities during the 16- month intervention period 
was 1187.2 and 909.0 per 100 000 population in the 
HIVST and SOC arms, respectively (adjusted RD 309.1, 
95% CI −95.5 to 713.7; table 2; online supplemental 
figure 1). Stratified by time period since study initia-
tion, the adjusted RD for periods of 0–5, 6–11 and 12–16 
months was 142.6 (95% CI −81.5 to 366.7), 194.8 (95% 
CI 31.4 to 358.1) and 28.3 (95% CI −186.5 to 129.9), 
respectively. There was no evidence for statistical differ-
ences measured (6–11 months vs 0–5 months: p value for 
interaction=0.51; 12–16 months vs 0–5 months: p value 
for interaction=0.42; online supplemental table 4).
Process outcomes
Consistent with the high number of HIVST kits distrib-
uted, there were large differences between arms in 
awareness and use of HIVST at endline. The propor-
tion of participants who had heard of HIVST at endline 
was 88.8% (2294/2582) in the HIVST arm and 31.5% 
(917/2908) in the SOC arm (table 3). Self- reported life-
time HIVST use was respectively 42.5% (1097/2582) in 
the HIVST arm, with uptake highest in young men aged 
20–24 years (58%) and adolescent boys (49.0%; online 
supplemental figure 2). Similar coverage was reported 
for HIVST use in the last 12 months. HIVST use was 8.3% 
(240/2908) in the SOC arm, with one cluster exposed 
to an external community- based HIVST programme in 
2017. Among participants who recently self- tested in the 
HIVST arm (n=794), most received HIVST kits from the 
CBDA (97.9%, n=777) and collected their kits at home 
(76.7%, n=609). Further, 0.8% (n=6) reported a new 
HIV- positive result and 2.0% (n=16) reported a repeat 
positive result, of whom 31.8% (7/22) linked to confirm-
atory HIV testing and 27.3% (6/22) initiated on ART.
Table 1 Comparison of endline population characteristics 
by study arm
HIVST SOC
n (%) n (%)
Baseline
Individual characteristics (n=2809) (n=2664)
Ever tested 82.2% (2308) 77.1% (2054)
Tested in the last 12 months 56.0% (1574) 48.4% (1289)
Endline
Household characteristics (n=1407) (n=1381)
Adults (median/range) 2 (1–7) 2 (1–9)
Children (median/range) 2 (0–8) 2 (0–9)
Household wealth index*
  Lowest 434 (32%) 468 (35.7%)
  Middle 456 (33.6%) 422 (32.2%)
  Highest 466 (34.4%) 421 (32.1%)
Individual characteristics (n=2582) (n=2908)
Male 1075 (41.6%) 1264 (43.5%)
Age (median/range) 31 (16–97) 31 (16–91)
Age group (years)
  16–19 366 (14.2%) 439 (15.1%)
  20–24 469 (18.2%) 558 (19.2%)
  25–39 931 (36.1%) 998 (34.3%)
  ≥40 816 (31.6%) 913 (31.4%)
Marital status
  Married or living together 1795 (69.5%) 1838 (63.2%)
  Separated, divorced or 
widowed
405 (15.7%) 438 (15.1%)
  Never married 382 (14.8%) 632 (21.7%)
Educational attainment
  None 463 (17.9%) 555 (19.1%)
  Primary 1745 (67.6%) 1898 (65.3%)
  Secondary or higher 374 (14.5%) 455 (15.6%)
Literate 1639 (63.5%) 1907 (65.6%)
Resident in last 12 months 2429 (94.1%) 2748 (94.5%)
Self- rated health status†
  Very good 662 (25.7%) 996 (34.3%)
  Good 1470 (57.0%) 1429 (49.1%)
  Fair 319 (12.4%) 320 (11.0%)
  Poor 128 (5.0%) 163 (5.6%)
Samples for the baseline and endline survey include different 
individuals.
*51 missing values in the HIVST arm and 70 missing values in the 
SOC arm.
†3 missing values in the HIVST arm.
HIVST, HIV self- testing; SOC, standard of care.
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Safety outcomes
At endline, 0.5% (4/794) of participants reported being 
forced to self- test or disclose their self- test results (table 3). 
Three events of social harm related to HIVST were 
reported, managed and resolved through the community 
reporting system: one case involved discrimination from 
household members for collecting an HIVST kit; two 
cases involved temporary separation between couples, 
with one event from self- testing and one event due to 
newly identified serodiscordancy within the couple. In 
an additional event reported to implementers in non- 
evaluation areas, a perinatally infected adolescent under 
the eligible age acquired an HIVST kit and suffered a 
highly stigmatising response following self- testing with 
her friends. These events have been described in detail 
elsewhere.17
DISCUSSION
The main findings from this cluster randomised trial were 
that door- to- door distribution of HIVST kits by CBDAs 
increased recent and lifetime HIV testing at population 
level in rural Malawi. Our primary outcome of recent 
testing increased by 16.1%. Lifetime testing increased by 
6.3%, with differences between arms most pronounced 
among priority subgroups: adolescents aged 16–19 years 
and men. The HIVST intervention did not show an effect 
on cumulative incidence of ART initiations at health 
facilities for the overall 16- month intervention period. 
HIVST use was reported by 42.5% of participants in the 
HIVST arm, with uptake highest among young men aged 
20–24 years and adolescent boys. Few serious adverse 
events were reported. Our results therefore support 
door- to- door HIVST as an effective and safe strategy that 
can be used to meet HIV testing needs in underserved 
rural populations.
Our study is one of three community- based randomised 
trials from rural settings in southern Africa that were 
implemented as part of STAR.14 19 20 Affordable, conve-
nient and safe HIV testing strategies are important for 
rural populations, who often have more pronounced 
barriers to accessing healthcare.13 The STAR trials had 
critical differences that can be used to guide policy and 
future research priorities. Our results showed increased 
recent and lifetime HIV testing from door- to- door 
HIVST, consistent with a separate Zambian trial, which 
added HIVST to an intensive community- based HIV 
programme.12 High coverage of lifetime testing (88.7%) 
and lifetime HIVST use (50.2%) was reported for both 
arms of the STAR Zimbabwe trial, which compared the 
impact of remuneration strategies under campaign- style 
distribution by CBDAs on linkage to HIV care.19 Our 
study, along with the Zimbabwe trial, implemented door- 
to- door distribution. In contrast, provision of HIVST 
kits at home, high- density community sites and health 
facilities under the STAR Zambia trial resulted in lower 
HIVST use (26.3%) and no measurable increase in life-
time or recent testing.20 Process outcomes, such as HIVST 
awareness, were also lower in Zambia than in Malawi and 
Zimbabwe, suggesting that door- to- door distribution can 
lead to higher penetration than broader community- 
based models.19 20
We showed encouraging uptake of HIVST, with minimal 
social harms reported. Uptake was highest among young 
men aged 20–24 years followed by adolescent boys aged 
16–19 years. Our study also reported increased lifetime 
HIV testing among adolescents and men. HIVST can 
bypass barriers that prevent uptake of standard HTS by 
these priority subgroups,10 21 with HIVST valued for the 
convenience and confidentiality afforded.5 22 However, 
our results demonstrated lower uptake compared with 
the STAR Zimbabwe trial, which evaluated more inten-
sive distribution across a shorter period of time.19 Simi-
larly, a previous study in urban Malawi reported 84% 
uptake from distribution of HIVST kits by community 
volunteers, which may indicate higher acceptability 
among urban counterparts.10 Understanding remaining 
demand- side barriers may allow for further optimisa-
tion of community- based HIVST strategies to maximise 
coverage and impact among underserved subgroups. 
Table 3 Fidelity to HIV self- testing intervention
HIVST SOC
n (%) n (%)
(n=2582) (n=2908)
Heard of self- testing* 2294 (88.8) 917 (31.5)
Ever self- tested† 1097 (42.5) 240 (8.3)
Self- tested in the last 12 
months‡
974 (37.7) 211 (7.3)




  CBDA 777 (97.9)
  Other distributor 17 (2.1)
Self- test collection location
  Home 609 (76.7)
  Other location 185 (23.3)
Self- test result§
  New positive 6 (0.8)
  Repeat positive 16 (2.0)
  Negative 771 (97.2)
Linked to confirmatory HIV 
testing (n=22)
7 (31.8)
Initiated on ART (n=22) 6 (27.3)
Forced to self- test or 
disclose self- test result
4 (0.5)
*1 missing value in the HIVST arm.
†1 missing value in the HIVST arm.
‡2 missing values in the HIVST arm.
§1 missing value in the HIVST arm.
ART, antiretroviral therapy; CBDA, community- based distribution 
agent; HIVST, HIV self- testing; SOC, standard of care.
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Alternative HIVST strategies should also be considered. 
In Malawi, facility- based provision of HIVST kits among 
outpatients increased coverage of HIV testing, especially 
among adolescents.23 Another study in Malawi found 
that secondary distribution to male partners of pregnant 
women extended testing coverage.21
Our study did not observe an increase in ART initia-
tions for the overall 16- month intervention period but 
in subgroup analysis for the 6–11 months’ postinterven-
tion period. Further, 0.8% of participants reported a new 
positive result from HIVST, with frequent repeat testing 
among participants already known to be HIV positive. 
Impact on ART uptake varied across STAR trials.24 A non- 
randomised evaluation accompanying the Zimbabwe 
trial estimated a 27% increase in ART initiation rates,19 
while no difference was observed in Zambia.20 Linkage to 
HIV care is practically difficult to capture, with potential 
for measurement errors.24 True impact on ART demand 
from HIVST will depend on the prevalence of untreated 
HIV, which has been declining in southern and eastern 
Africa.2 The intensity and reach of HIVST distribution 
strategies will also influence population- level impact. 
Additionally, interventions to encourage timely linkage 
to health facilities may be required, such as provision 
of home- based HIV care or more substantial financial 
incentives.11 21
The benefits of community- based HTS are well estab-
lished, with the main barrier to implementation including 
high cost per test and cost per new diagnosis, especially as 
countries reach the ‘First 90’ targets.25 Economic analysis 
of our intervention is reported separately.26 CBDA distri-
bution showed average cost of 2017 US$8.15 per HIVST 
kit distributed, with the main cost contributors including 
personnel and HIVST kits.26 Unit cost of community- 
based HIVST was higher than the average cost of facility- 
based HTS (2016 US$4.92) and facility- based HIVST 
(US$4.99) in Malawi.23 27 While community- based HIVST 
is likely to maintain higher levels of knowledge of recent 
HIV status than standard HTS alone, sustainable provi-
sion will require further reductions in costs and optimi-
sation of linkage to HIV treatment and prevention. For 
example, providing periodic campaigns is likely to be 
less costly than maintaining a continuous programme, 
especially if targeted to high- prevalence populations or 
underserved subgroups with ongoing HIV risk. Alterna-
tively, a community- led approach for delivering HIVST 
has potential to further reduce costs.28
The main strength of this study is the use of a robust 
cluster randomised design to report on the effectiveness 
and safety of large- scale implementation of community- 
based HIVST. Further, CBDAs are commonly used to 
distribute health commodities in Malawi, with our find-
ings potentially generalisable to settings in sub- Saharan 
Africa with similar community health cadres. We also 
add to the body of evidence on effective strategies for 
expanding HIV testing coverage in rural, HIV- prevalent 
populations and among population subgroups with 
substantial undiagnosed HIV.
Limitations included HIV testing outcomes that were 
self- reported and therefore susceptible to misreporting. 
ART initiations may be underestimated if study residents 
accessed non- study health facilities, which we aimed to 
minimise with our inclusion criteria of health facilities. 
Non- participation in the endline survey could result in 
ascertainment bias, with response rates lower among 
men than women. We did not account for household- 
level clustering, though this was unlikely to have altered 
our findings.29 We discontinued second randomisation of 
home- based HIV care in the HIVST arm; however, the 
outcomes reported in this study were not affected. Data 
on social harms were passively collected through commu-
nity reporting systems, potentially under- reporting 
the number of adverse events. Finally, our findings are 
limited to our intervention design, which included door- 
to- door implementation through remunerated CBDAs.
CONCLUSION
Door- to- door distribution of HIVST kits by CBDAs 
increased recent and lifetime HIV testing in rural, under-
served populations, including among adolescents 16–19 
years and men. ART initiations showed no differences 
between arms for the overall 16- month intervention 
period. HIVST was very acceptable and safe, with uptake 
highest among young men and adolescent boys. Door- 
to- door HIVST demonstrates significant potential to 
contribute to HIV elimination goals in priority settings. 
Further, as countries approach the ‘First 90’ targets, this 
approach could be adapted for periodic implementation 
to meet the ongoing need for HTS in settings with high 
undiagnosed HIV.
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